LLY vs AMGN — which stock performed better?

Eli Lilly and Company (LLY) versus Amgen Inc. (AMGN), Healthcare / Biotechnology, on 2026-06-16.

Result

Eli Lilly and Company (LLY) performed better on 2026-06-16. LLY moved -0.320%, AMGN moved -1.310%.

Why these two companies

Both companies are competing for dominance in the rapidly expanding obesity and weight-loss drug market, one of the most valuable therapeutic categories in modern medicine. The market will be answering a fundamental question: can Amgen's experimental monthly treatment, MariTide, credibly challenge Eli Lilly's entrenched GLP-1 leadership, or will Lilly's pipeline depth and first-mover advantage prove insurmountable?

The research

The healthcare sector is currently fixated on the obesity and weight-loss drug market, which analysts believe could become one of the largest pharmaceutical categories in history. With approximately 890 million people classified as obese globally according to the World Health Organization, the commercial opportunity is immense. Both Eli Lilly and Amgen are positioning themselves as key beneficiaries, but from very different vantage points.

Eli Lilly (LLY) is the reigning market leader in obesity treatment. Its flagship injectable Zepbound — and its diabetes equivalent Mounjaro — have become among the world's best-selling medicines. Lilly has also launched Foundayo, a small-molecule oral pill, earlier this year, adding a new dimension to its portfolio. Most recently, at the American Diabetes Association's Scientific Sessions, Lilly presented Phase 3 data for its next-generation triple-acting drug, retatrutide, which targets three gut hormones simultaneously. Participants in the trial lost an average of 28% of their body weight — a level of efficacy analysts described as approaching the results of bariatric surgery. Lilly's strategy is to build a layered portfolio across injectables, pills, and next-generation therapies to maintain its leadership through the 2030s.

Amgen (AMGN) is the most credible challenger to Lilly's dominance among large-cap NASDAQ-listed biotechs. Its experimental drug, MariTide (maridebart cafraglutide), is being developed as a monthly or potentially quarterly injection — a significant convenience improvement over the current standard of weekly shots. Phase 2 data showed patients losing up to 20% of their body weight over 52 weeks without reaching a plateau, a result that impressed some analysts while leaving others wanting more. Amgen presented additional cardiometabolic data at the ADA meeting and is actively advancing MariTide into Phase 3 trials. The company also beat Q1 2026 earnings estimates (EPS of $5.15 vs. $4.77 expected), and growing investor enthusiasm around MariTide has been cited as a key reason for renewed interest in the stock.

The core tension in this matchup is between proven dominance and disruptive potential. Lilly has the products, the revenue, and the pipeline momentum. Amgen has a differentiated dosing story and a lower valuation that could offer more upside if MariTide data continues to impress. Players should consider how the broader market environment — including the FOMC meeting currently underway — might affect higher-valuation growth stocks like Lilly versus more value-oriented names like Amgen.